PMID- 19662218
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1177-2719 (Print)
IS  - 1177-2719 (Electronic)
IS  - 1177-2719 (Linking)
VI  - 2
DP  - 2007 Oct 16
TI  - Validation of candidate serum ovarian cancer biomarkers for early detection.
PG  - 369-75
AB  - OBJECTIVE: We have previously analyzed protein profiles using Surface Enhanced 
      Laser Desorption and Ionization Time-Of-Flight Mass Spectroscopy (SELDI-TOF-MS) 
      [Kozak et al. 2003, Proc. Natl. Acad. Sci. U.S.A. 100:12343-8] and identified 3 
      differentially expressed serum proteins for the diagnosis of ovarian cancer (OC) 
      [Kozak et al. 2005, Proteomics, 5:4589-96], namely, apolipoprotein A-I (apoA-I), 
      transthyretin (TTR) and transferin (TF). The objective of the present study is to 
      determine the efficacy of the three OC biomarkers for the detection of early 
      stage (ES) OC, in direct comparison to CA125. METHODS: The levels of CA125, 
      apoA-I, TTR and TF were measured in 392 serum samples [82 women with normal 
      ovaries (N), 24 women with benign ovarian tumors (B), 85 women with ovarian 
      tumors of low malignant potential (LMP), 126 women with early stage ovarian 
      cancer (ESOC), and 75 women with late stage ovarian cancer (LSOC)], obtained 
      through the GOG and Cooperative Human Tissue Network. Following statistical 
      analysis, multivariate regression models were built to evaluate the utility of 
      the three OC markers in early detection. RESULTS: Multiple logistic regression 
      models (MLRM) utilizing all biomarker values (CA125, TTR, TF and apoA-I) from all 
      histological subtypes (serous, mucinous, and endometrioid adenocarcinoma) 
      distinguished normal samples from LMP with 91% sensitivity (specificity 92%), and 
      normal samples from ESOC with a sensitivity of 89% (specificity 92%). MLRM, 
      utilizing values of all four markers from only the mucinous histological subtype 
      showed that collectively, CA125, TTR, TF and apoA-I, were able to distinguish 
      normal samples from mucinous LMP with 90% sensitivity, and further distinguished 
      normal samples from early stage mucinous ovarian cancer with a sensitivity of 
      95%. In contrast, in serum samples from patients with mucinous tumors, CA125 
      alone was able to distinguish normal samples from LMP and early stage ovarian 
      cancer with a sensitivity of only 46% and 47%, respectively. Furthermore, 
      collectively, apoA-I, TTR and TF (excluding CA-125) distinguished i) normal 
      samples from samples representing all histopathologic subtypes of LMP, with a 
      sensitivity of 73%, ii) normal samples from ESOC with a sensitivity of 84% and 
      iii) normal samples from LSOC with a sensitivity of 97%. More strikingly, the 
      sensitivity in distinguishing normal versus mucinous ESOC, utilizing apoA-I, TF 
      and TTR (CA-125 excluded), was 95% (specificity 86%; AUC 95%). CONCLUSIONS: These 
      results suggest that the biomarker panel consisting of apoA-I, TTR and TF may 
      significantly improve early detection of OC.
FAU - Su, Feng
AU  - Su F
AD  - Department of Obstetrics and Gynecology, University of California, Los Angeles, 
      CA 90095, U.S.A.
FAU - Lang, Jennifer
AU  - Lang J
FAU - Kumar, Ashutosh
AU  - Kumar A
FAU - Ng, Carey
AU  - Ng C
FAU - Hsieh, Brian
AU  - Hsieh B
FAU - Suchard, Marc A
AU  - Suchard MA
FAU - Reddy, Srinivasa T
AU  - Reddy ST
FAU - Farias-Eisner, Robin
AU  - Farias-Eisner R
LA  - eng
PT  - Journal Article
DEP - 20071016
PL  - United States
TA  - Biomark Insights
JT  - Biomarker insights
JID - 101288638
PMC - PMC2717832
OTO - NOTNLM
OT  - Mucinous
OT  - Ovarian cancer
OT  - Serous
OT  - Serum biomarker
EDAT- 2007/01/01 00:00
MHDA- 2007/01/01 00:01
PMCR- 2007/10/16
CRDT- 2009/08/08 09:00
PHST- 2009/08/08 09:00 [entrez]
PHST- 2007/01/01 00:00 [pubmed]
PHST- 2007/01/01 00:01 [medline]
PHST- 2007/10/16 00:00 [pmc-release]
AID - bmi-2007-369 [pii]
PST - epublish
SO  - Biomark Insights. 2007 Oct 16;2:369-75.